Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)

Sundby Hall, Kirsten; Bruland, Øyvind S.; Bjerkehagen, Bodil; Zaikova, Olga; Engellau, Jacob; Hagberg, Oskar; Hansson, Lina; Hagberg, Hans; Ahlström, Marie; Knobel, Heidi; Papworth, Karin; Zemmler, Maja; Goplen, Dorota; Bauer, Henrik C.F.; Eriksson, Mikael

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)

Mark

Sundby Hall, Kirsten ; Bruland, Øyvind S. ; Bjerkehagen, Bodil ; Zaikova, Olga ; Engellau, Jacob ^LU ; Hagberg, Oskar ^LU ; Hansson, Lina ; Hagberg, Hans ; Ahlström, Marie and Knobel, Heidi , et al. (2018) In European Journal of Cancer 99. p.78-85

Abstract: Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. Methods: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II–III) and either vascular invasion or at least two of the following criteria: tumour size ≥8.0 cm, infiltrative growth and necrosis. Six... (More); Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. Methods: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II–III) and either vascular invasion or at least two of the following criteria: tumour size ≥8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m²) and ifosfamide (6 g/m²) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4. Results: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2–8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1–78.4) with a local recurrence rate of 14.0% (95% CI: 7.8–20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2–8.7). The five-year OS was 76.1% (95% CI: 68.8–84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death. Conclusions: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.
(Less)

Please use this url to cite or link to this publication: https://lup.lub.lu.se/record/4c4eb951-eb77-4b3d-8e13-d9173093a3d0

author

Sundby Hall, Kirsten ; Bruland, Øyvind S. ; Bjerkehagen, Bodil ; Zaikova, Olga ; Engellau, Jacob ^LU ; Hagberg, Oskar ^LU ; Hansson, Lina ; Hagberg, Hans ; Ahlström, Marie and Knobel, Heidi , et al. (More)

Sundby Hall, Kirsten ; Bruland, Øyvind S. ; Bjerkehagen, Bodil ; Zaikova, Olga ; Engellau, Jacob ^LU ; Hagberg, Oskar ^LU ; Hansson, Lina ; Hagberg, Hans ; Ahlström, Marie ; Knobel, Heidi ; Papworth, Karin ; Zemmler, Maja ; Goplen, Dorota ; Bauer, Henrik C.F. and Eriksson, Mikael ^LU

(Less)

organization

Tumor microenvironment

publishing date

2018-08-01

type

Contribution to journal

publication status

published

subject

Cancer and Oncology

keywords

Adjuvant treatment, Growth pattern, Necrosis, Prognostic factors, Soft tissue sarcoma, Survival, Tumour size, Vascular invasion

in

European Journal of Cancer

volume

99

pages

8 pages

publisher

Elsevier

external identifiers

scopus:85048786554
pmid:29929092

ISSN

0959-8049

DOI

10.1016/j.ejca.2018.05.011

language

English

LU publication?

yes

id

4c4eb951-eb77-4b3d-8e13-d9173093a3d0

date added to LUP

2018-07-04 12:10:22

date last changed

2024-04-15 08:57:57

@article{4c4eb951-eb77-4b3d-8e13-d9173093a3d0,
  abstract     = {{<p>Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. Methods: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II–III) and either vascular invasion or at least two of the following criteria: tumour size ≥8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m<sup>2</sup>) and ifosfamide (6 g/m<sup>2</sup>) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4. Results: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2–8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1–78.4) with a local recurrence rate of 14.0% (95% CI: 7.8–20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2–8.7). The five-year OS was 76.1% (95% CI: 68.8–84.2). Tumour size, deep location and reduced dose intensity (&lt;80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death. Conclusions: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.</p>}},
  author       = {{Sundby Hall, Kirsten and Bruland, Øyvind S. and Bjerkehagen, Bodil and Zaikova, Olga and Engellau, Jacob and Hagberg, Oskar and Hansson, Lina and Hagberg, Hans and Ahlström, Marie and Knobel, Heidi and Papworth, Karin and Zemmler, Maja and Goplen, Dorota and Bauer, Henrik C.F. and Eriksson, Mikael}},
  issn         = {{0959-8049}},
  keywords     = {{Adjuvant treatment; Growth pattern; Necrosis; Prognostic factors; Soft tissue sarcoma; Survival; Tumour size; Vascular invasion}},
  language     = {{eng}},
  month        = {{08}},
  pages        = {{78--85}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)}},
  url          = {{http://dx.doi.org/10.1016/j.ejca.2018.05.011}},
  doi          = {{10.1016/j.ejca.2018.05.011}},
  volume       = {{99}},
  year         = {{2018}},
}

Lund University Publications

LUND UNIVERSITY LIBRARIES

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)